QT Imaging Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q2 2026 revenue was $7.4 million, a 103% increase from $3.7 million in Q2 2025. Year-to-date revenue reached $14 million, compared to $6.5 million in the same period last year.

Gross Margin: 41% in Q2 2026, down from 50% in Q2 2025, attributed to higher costs associated with current sales.

Operating Expenses: Increased to $4.9 million from $2.9 million year-over-year, driven by higher employee compensation, professional services, and marketing costs.

Net Loss: $11.1 million, compared to a net loss of $4 million in Q2 2025, which included an $8.3 million non-cash loss due to debt modification.

Cash Position: As of August 7, 2026, cash and restricted cash totaled approximately $14.2 million, up from $11 million at the end of June 2026.

2Strategic Updates and Business Highlights

Product Shipments: 15 breast acoustic CT scanners were shipped in Q2 2026, with plans for 15 more in Q3 and 17 in Q4.

Commercial Strategy: Expanded U.S. commercial team with new regional sales VPs to enhance direct sales efforts alongside existing partnerships, particularly with NXT Imaging.

International Expansion: Gained regulatory clearances in Saudi Arabia and Israel, with plans for further market penetration in the Gulf region.

Clinical Studies: Ongoing studies to validate the technology's effectiveness, including a significant study at Rambam Healthcare Campus in Israel focusing on high-risk populations.

Innovation: Continued development of software and hardware enhancements, including a new imaging viewer and cloud-based capabilities for improved clinical workflows.

3Forward Guidance and Outlook

2026 Revenue Guidance: Affirmed guidance of approximately $39 million, more than double the revenue from 2025, based on expected scanner shipments and direct sales contributions.

Strategic Focus: Priorities include accelerating commercial adoption, strengthening clinical evidence, expanding global access, and advancing the quantitative imaging platform.

4Bad News, Challenges, or Points of Concern

Declining Gross Margin: The drop in gross margin from the previous year indicates rising costs that may impact profitability.

Increased Operating Loss: The net loss has widened significantly, raising concerns about financial sustainability amidst growing expenses.

Geopolitical Risks: Ongoing geopolitical tensions in the Gulf region may affect commercial activities and customer engagement.

Sales Execution: Although the company is expanding its sales force, the pace of scanner placements remains slower than desired, indicating potential challenges in market penetration.

5Notable Q&A Insights

Pakistan Market: The company is moving forward with a sales agent agreement in Pakistan, expecting to ship systems soon.

U.S. Sales Strategy: The direct sales team is expected to take on more responsibilities in 2027, with a focus on imaging centers and hospitals.

Clinical Study Goals: The new study at Mayo Clinic aims to validate QT scan against MRI, with hopes to reduce unnecessary biopsies.

Facility Move: The company is transitioning to a new facility in Petaluma, California, which will enhance operational capacity while reducing costs. Overall, QT Imaging demonstrated strong revenue growth and strategic advancements in Q2 2026, but faces challenges related to rising costs, increased losses, and external geopolitical factors. The company remains focused on expanding its market presence and enhancing its technology platform.